{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:52:07Z","timestamp":1770065527775,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.clinbiochem.2023.110649","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T12:02:50Z","timestamp":1695211370000},"page":"110649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Treatment target achievement in patients with familial hypercholesterolemia: A real-world descriptive study"],"prefix":"10.1016","volume":"120","author":[{"given":"Simon","family":"Faubert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7555-1275","authenticated-orcid":false,"given":"Martine","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Baass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-1852","authenticated-orcid":false,"given":"Sophie","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.clinbiochem.2023.110649_b0005","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"22","key":"10.1016\/j.clinbiochem.2023.110649_b0010","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2023.110649_b0015","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.clinbiochem.2023.110649_b0020","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2023.110649_b0025","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.atherosclerosis.2018.08.010","article-title":"French FH Registry Group. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: the French Familial Hypercholesterolemia Registry","volume":"277","author":"B\u00e9liard","year":"2018","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.clinbiochem.2023.110649_b0030","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.clinbiochem.2023.110649_b0035","doi-asserted-by":"crossref","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227-337.","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"10.1016\/j.clinbiochem.2023.110649_b0040","first-page":"385","article-title":"Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study","volume":"33","author":"Brunham","year":"2017","journal-title":"Can. J. Cardiol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2023.110649_b0045","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2019.05.004","article-title":"Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International ChoLesterol management Practice Study","volume":"13","author":"Blom","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2023.110649_b0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","article-title":"PCSK9 inhibitors: clinical evidence and implementation","volume":"16","author":"Sabatine","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.clinbiochem.2023.110649_b0055","unstructured":"Institut national d\u2019excellence en sant\u00e9 et en services sociaux. Recommandation de l\u2019INESSS. Available at: https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Inscription_medicaments\/Avis_au_ministre\/Fevrier_2021\/Praluent_Repatha_modification_critere_2021_01.pdf. Accessed February 2, 2023."},{"issue":"5","key":"10.1016\/j.clinbiochem.2023.110649_b0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2023.110649_b0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-020-0669-2","article-title":"Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias","volume":"13","author":"Dron","year":"2020","journal-title":"BMC Med. Genomics"},{"issue":"3","key":"10.1016\/j.clinbiochem.2023.110649_b0070","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCGENETICS.116.001381","article-title":"Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry","volume":"9","author":"deGoma","year":"2016","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"11","key":"10.1016\/j.clinbiochem.2023.110649_b0075","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.numecd.2020.06.028","article-title":"Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study","volume":"30","author":"D'Erasmo","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.clinbiochem.2023.110649_b0080","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2014.02.021","article-title":"Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects","volume":"234","author":"B\u00e9liard","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2023.110649_b0085","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2023.110649_b0090","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.atherosclerosis.2018.08.014","article-title":"The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia","volume":"277","author":"Lali\u0107","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2023.110649_b0095","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"SAFEHEART Investigators. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.clinbiochem.2023.110649_b0100","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.atherosclerosis.2018.08.050","article-title":"Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry","volume":"277","author":"Schmidt","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2023.110649_b0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2017.05.013","article-title":"Dyslipidemia Registry of the Spanish Arteriosclerosis Society. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?","volume":"262","author":"Masana","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2023.110649_b0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.atherosclerosis.2018.08.008","article-title":"Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry","volume":"277","author":"Vrablik","year":"2018","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.clinbiochem.2023.110649_b0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.clinbiochem.2023.110649_b0120","doi-asserted-by":"crossref","first-page":"e9220","DOI":"10.1371\/journal.pone.0009220","article-title":"Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal","volume":"5","author":"Huijgen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2023.110649_b0125","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clinbiochem.2023.110649_b0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"18","key":"10.1016\/j.clinbiochem.2023.110649_b0135","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.clinbiochem.2023.110649_b0140","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2023.110649_b0145","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacl.2022.12.002","article-title":"Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience","volume":"17","author":"Paquette","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.clinbiochem.2023.110649_b0150","unstructured":"Statistics Canada. Table 17-10-0005-01 Population estimates on July 1st, by age and sex. Available at: https:\/\/doi.org\/10.25318\/1710000501-eng. Accessed February 2, 2023."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912023001777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912023001777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T16:00:16Z","timestamp":1757865616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912023001777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":30,"alternative-id":["S0009912023001777"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2023.110649","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment target achievement in patients with familial hypercholesterolemia: A real-world descriptive study","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2023.110649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110649"}}